Shots:
- Following the EC approval, Formycon & Klinge Biopharma have reported the UK MHRA’s approval of FYB203, biosimilar of Eylea (aflibercept), under the brand name: Ahzantive
- The biosimilar is intended to treat Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases incl. Diabetic Macular Edema (DME), visual impairment due to Myopic Choroidal Neovascularization (CNV) & Macular Edema following Retinal Vein Occlusion (RVO)
- Furthermore, Formycon & Teva Pharmaceuticals have partnered for the semi-exclusive commercialization of FYB203 in major parts of EU, including the UK & Israel. Formycon had concluded a product supply agreement with Teva, which is already marketing Formycon’s FYB201 ranibizumab biosimilar (Ongavia) in UK and will leverage its existing ophthalmology infrastructure and distribution channels
Ref: Formycon | Image: Formycon
Related News:- Formycon Reports the EC’s Approval of FYB203 (Biosimilar, Eylea) Under the Brand Names Ahzantive and Baiama
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
